P178 The impact of peripheral articular manifestations on the efficacy of ixekizumab in patients with radiographic axial spondyloarthritis
Conclusion IXE led to significant improvements versus PBO in all efficacy and HRQoL endpoints at Week 16 in the integrated dataset, irrespective of PA manifestations at baseline. P178 Table 1:a) Responder rates at Week 16 for the intent-to-treat population, number (%)No peripheral articular manifestations at baselinePeripheral articular manifestations at baselinePBOADAQ2WIEQ4WIXEQ2WPBOADAQ2WIXEQ4WIXEQ2WIntegrated datasetaaN=71N/AN=63N=66N=119N/AN=132N=115ASAS4011.5N/A29 (46.0) ‡‡28 (42.4) ‡‡18 (15.1)N/A39 (29.5) ††45 (39.1) ‡‡ASDAS<2.18 (11.3)N/A24 (38.1) ‡‡23 (34.8) ††8 (6.7)N/A31 (23.5) ‡...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P177 Management of patients with axSpA: an audit against the NICE diagnosis and management of adults with spondyloarthritis quality standard, QS170, and clinical practice guidelines
Conclusion Performing this audit ensured that we benchmarked our service against NICE QS170 and clinical practice guidelines, to identify deficient care aspects and enable action plans to be developed to improve patient care.Disclosure R. Sengupta: Honoraria; RS has received honoraria/expenses/research grants from AbbVie, Biogen, Celgene, Lilly, MSD, Novartis, Pfizer, UCB.M. Savino: Grants/research support; MS received expenses for data collection within this study from Novartis.E. Reilly: Grants/research support; ER has received research grants from Actelion and Celgene Corporation outside of this work. ER has also re...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P176 Self-management of depression in axial spondyloarthritis using internet-delivered cognitive behavioural therapy: a feasibility study
Conclusion iCBT may be a useful intervention for axSpA patients with depression. However, low levels of engagement and high attrition rates (common in intervention studies of depression) resulted in only 17% completing the full programme. These figures will be essential for planning of future clinical trial s in this area. Future work could also consider strategies to promote engagement and use and potential adaptation of interventional content for iCBT delivery in this population.Disclosure S.S. Zhao: None.D. Richards: Other; DR is the Chief Science Officer for SilverCloud Health.N. Goodson: None. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P175 Comorbidities in psoriatic arthritis: a systematic review and meta-analysis
Conclusion Comorbidities, particularly cardiometabolic disorders, were highly prevalent in PsA and more common than in controls. Comorbidities were associated with adverse disease features, but more research is needed on their impact on longitudinal clinical outcomes.Disclosure Z.J. Syrimi: None.S. Gupta: None.S.S. Zhao: None.D.M. Hughes: None. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P174 Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
Conclusion PsARC responses greater than placebo were seen as early as W2, with stable response rates from W12 in both SELECT-PsA-1 and SELECT-PsA-2. Statistically significantly higher response rates versus ADA were observed by W20. Differences in W24 PsARC responses versus placebo and versus ADA were genera lly consistent across baseline characteristics and UPA-15mg mono/combination therapy. P174 Table 1:Modified PsARC response rates at W2 to W24 in SELECT-PsA-1 and SELECT-PsA-2 trialsStudy and week of assessmentTreatment armResponse rate % (95% CI)Response rate difference % (95% CI) UPA-placeboRespo nse rate differenc...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P173 Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active PsA and inadequate response to non-biologic DMARDs (SELECT-PSA-1): a double-blind, randomised controlled phase III trial
Conclusion In this non-bDMARD-IR PsA population UPA15/30 demonstrated improvement in musculoskeletal symptoms, psoriasis, physical function, pain, fatigue and inhibited radiographic progression; improvements observed by Wk2. At Wk12, UPA15/30 were non-inferior to ADA for ACR20, with superiority demonstrated for UPA30. Greater percentages of UPA vs PBO patients achieved stringent disease control measures (MDA, ACR50/70, sIGA 0/1). No new safety signals were identified compared to the safety profile observed in RA.Disclosure I. McInnes: Other; I.McI has received research grants and honoraria from Abbvie, BMS, Celgene, No...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P125 The relationship between mid-life pain and cognitive impairment: a prospective, population-based study
Conclusion After 13 years’ follow-up, severe bodily pain but not multi-joint pain in mid-life was associated with subsequent cognitive impairment, determined by MMSE ≤26. Women with severe bodily pain and multi-joint pain had higher crude all-cause mortality rate, but this was not statistically signific ant after adjustment. Pain interference displayed a stronger association with cognitive impairment; this may reflect the impact of pain on functional status. This study represents the first time the consequences of mid-life pain on later life cognition were examined. Chronic pain, which is largely u ntreated, may thus...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P124 Are chronic pain syndromes associated with a unique cytokine profile? A systematic review and meta-analysis
Conclusion We found significant differences in peripheral blood cytokine profiles of CPS patients compared to HC. However, the distinctive profile associated with CPS includes both pro-inflammatory (TNF-α, IL-6, IL-8), and anti-inflammatory cytokines (IL-10) in pooled analysis, as well as chemokine (eotaxi n) signatures.Disclosure L. Furtado O'Mahony: None.A. Srivastava: None.P. Mehta: None.C. Ciurtin: None. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P123 Evaluating the performance of ACR, SLICC and EULAR/ACR classification criteria in childhood onset systemic lupus erythematosus
Conclusion In this cSLE population, the EULAR/ACR criteria scored better in sensitivity at first, one year and last follow up; while the ACR 1997 scored better in specificity at first, one year and last follow up. However, if the EULAR/ACR cut score ≥ 13 (rather than traditional cut-score ≥ 10) then it an equivalent specificity to ACR 1997 at the expense of lower sensitivity.Disclosure R. Abdwani: None.E. Al Masroori: None.E. Abdalla: None.S. Al Abrawi: None.I. Al Zakwani: None. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P121 The efficacy of treatment interventions on fatigue in adolescents with juvenile idiopathic arthritis: a literature review
Conclusion Fatigue is a significant problem in JIA during adolescence and influences quality of life. Improvements in fatigue with non-pharmacological interventions have been reported. However, at present, data is insufficient to conclusively decide which treatment intervention is most efficacious in treati ng fatigue in young people with JIA. Fatigue should be considered as an important outcome measure for the management of JIA in future evaluations of interventions.Disclosure S. Moshtael: None.S. Khanom: None.J.E. McDonagh: None. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P120 Self-reported disease activity was the main determinant of the perceived impact of COVID-19 pandemic on adolescent and young patients with juvenile dermatomyositis (JDM) and juvenile onset systemic lupus erythematosus (JSLE)
Conclusion The preliminary analysis of our survey showed that patient-reported COVID-19 concern during the pandemic was strongly determined by the self-reported disease activity irrespective of patients’ sex, despite significantly increased concern in the female compared to male patients, and association with disease duration in male patients only. We propose that further strategies for better patient support during the pandemic should focus on their optimal disease control as well as take into consideration the sex-biased patient concerns. P120 Table 1:FemaleMalep-valueNumber389Current age mean ( IQR)22.21 (18.25- 2...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P119 Average percent fat is associated with decreased bone mineral density at the hip but increase at the spine longitudinally, where weight shows a positive association at all anatomical locations
Conclusion The negative association seen with average percent fat at the hip could reflect the potential negative endocrine effects of fat, and the effect of localized inflammation at the hip. Increased adiposity is also linked to sarcopenia, and further body compositional changes. However, the potential ne gative effects of increased adiposity at the abdomen and spine are potentially overridden by the increased biomechanical loading generated by the increased adiposity, highlighted by weight’s positive association with BMD at the spine. The average percent fat results are not mirrored with weight at the hip. This high...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P118 Co-design of a model Fracture Liaison Service consultation: a Delphi survey with patients and clinicians
Conclusion The Delphi survey has informed iFraP intervention development by highlighting essential and optional FLS consultation content. Findings also provide insight into aspects of current osteoporosis clinical guidelines deemed appropriate in nurse/allied health professional led FLSs.Disclosure L. Bullock: None.C. Jinks: Grants/research support; CJ is part funded by the NIHR Applied Research Collaboration (ARC) West Midlands.F. Crawford-Manning: Grants/research support; FCM is part funded by the NIHR Clinical Research Network Scholar Programme.S. Leyland: None.J. Fleming: None.E.M. Clark: None.E. Cottrell: None.J. ...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P117 Exploring experiences of Fracture Liaison Services and perceptions of a new decision tool to support patient and clinician decisions: a focus group study
Conclusion These novel findings illustrate the experience of FLS consultations from three perspectives. They highlight FLS clinicians’ clinical decision-support needs and patients’ unmet need for clear information that addresses their medication concerns. Overall, the iFraP intervention was viewed as ac ceptable, with the potential to support clinicians’ decision-making and to facilitate informed decision-making. Differences in FLS configuration and a move to more remote consulting may mean the intervention needs to be adaptable to different settings to address barriers to implementation.Disclosure L. Bullock: No...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P098 Higher self-reported depression, anxiety and MSK scores in patients with non-inflammatory compared to inflammatory rheumatic diseases irrespective of age and gender
Conclusion The preliminary analysis of our study showed that patient-reported anxiety, depression and MSK outcomes were significantly higher in patients with non-inflammatory compared to those with inflammatory rheumatic conditions, and that the diagnosis category was the strongest determinant for anxiety a nd depression.Disclosure J.R. Henty: None.C. Ciurtin: None.E. Stefanova: None.B. Ellis: None.A. Kocsis: None. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
